XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
  Hypertension
  CAD
  Myocardial Infarction
  CHF
  Clinical Trials
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Cardiology Channel
subscribe to Cardiology newsletter

Latest Research : Cardiology

   DISCUSS   |   EMAIL   |   PRINT
Nebivolol May Restore Cardiovascular Function in African Americans
Mar 8, 2006, 21:38, Reviewed by: Dr. Priya Saxena

�It is very rare that we see a dual positive effect of a drug in medical treatments,�

 
Nebivolol, a drug for treatment of high blood pressure already available in Europe, may restore damaged cardiovascular functions in African Americans, according to a recent laboratory study at Ohio University.

Tadeusz Malinski, Marvin & Ann Dilley White Professor of Chemistry and Biochemistry, found that the drug, currently under review by the U.S. Food and Drug Administration, acts on the level of oxidants lining the cardiovascular system and can restore levels of nitric oxide and reduce oxidative stress. A deficiency in nitric oxide and high oxidative stress can cause a variety of health problems, including heart attacks, stroke and heart failure, as well as kidney failure and diabetes.

The study was published in a recent issue of Circulation, an American Heart Association Journal, and involved collaborators from Harvard Medical School and Elucida Research in Massachusetts.

In a healthy cardiovascular system, there is a fine balance between nitric oxide and oxidative stress. Nitric oxide controls blood flow and relaxes blood vessels, which lowers blood pressure. The nitric oxide is released by endothelial cells, a monolayer of cells lining blood vessels.

About a year ago, Malinski�s research team discovered that African Americans potentially have a better nitric oxide generating system than people of other ethnicities, the researcher reported. Due to a molecular deficiency, however, the system becomes self-destructive by also generating high concentrations of oxidative species that diminish the level of good nitric oxide and increase oxidative stress to the level observed in a diseased state. The prevalence of this problem can be blamed for the high mortality rate of African Americans between 43 and 64 years of age, which is five to six times higher than that of other ethnic groups, Malinski said.

That�s where nebivolol may come in. The drug is part of a new generation of beta-blockers, which are standard treatments for high blood pressure. The researchers studied multiple versions of these beta-blockers and found that, besides lowering blood pressure, nebivolol also restored the function of the nitric oxide system in the cell samples.

�It is very rare that we see a dual positive effect of a drug in medical treatments,� Malinski said.

In the recent study, scientists used nanosensors to test levels of nitric oxide, as well as molecules involved in the oxidative stress, in single cells from donors of various ethnic backgrounds. Using nanosensors 1,000 times smaller than a human hair, the researchers could take real-time measurements of nitric oxide levels before and after nebivolol was administered. This nanomedical approach allowed the research to progress much faster than it would have with traditional methods of measuring nitric oxide levels.

�The drug restores correct balance between good nitric oxide and damaging oxidative stress, and can in fact restore the vital function of endothelial tissue to a level similar in other ethnic groups,� Malinski said of his team�s findings. �Previous treatments only slowed progression of the damage, while nebivolol may actually be able to correct the problems.�

Malinski and other researchers are currently investigating possible uses of the drug to prevent damage to the cardiovascular system.
 

- The study was published in a recent issue of Circulation, an American Heart Association Journal
 

Ohio University

 
Subscribe to Cardiology Newsletter
E-mail Address:

 

Co-authors were Adam Jacoby and Leszek Kalinowski of Ohio University, Preston Mason Professor of Harvard Medical School and Robert Jacob of Elucida Research in Massachusetts.

The study was funded by the Marvin and Ann Dilley White Endowment and the Biomimetic Nanoscience and Nanotechnology Initiative, which part of a larger $8 million NanoBioTechnology Initiative that is one of three of Ohio University�s major research priorities.


Related Cardiology News

Seven-point system gauges seriousness of heart failure in elderly
Uric acid levels closely related to hypertension in Blacks
American College of Cardiology announces new initiative to improve safety for patients with Acute Coronary Syndromes
Is TROPHY misleading?
Fortified orange juice decreases not only cholesterol but also CRP
Heart Disease: Blame it on genes!
Famotidine may help to slow progression of chronic heart failure
Atherothrombotic disease is not just a 'western' problem
Changing normal heart cells into pacemakers
Ilk gene underlies heart failure


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us